Osocimab in adults with end-stage renal disease on regular hemodialysis

Phase 2, randomised, double-blind trial of osocimab in thromboembolism and thrombosis (4 arms), sponsored by Bayer. Primary endpoints: Composite of major and clinically relevant non-major bleeding events and Composite of moderate and severe adverse events and serious adverse events. Started Feb 2021; status: active, not recruiting.